联合PSMA-PET与PROMISE重新定义前列腺癌疾病分期与风险:一项多中心回顾性研究
这项多中心回顾性研究纳入2414例前列腺癌患者,基于PSMA-PET的PROMISE标准(PPP)构建定量与可视化列线图预测总生存,并在内部与外部验证队列中评估,C指数分别为0.80和0.77(定量)及0.78和0.77(可视化);定量PPP列线图在初始分期、生化复发和NCCN全分期中优于部分传统风险评分,但与GAFITA列线图在转移性激素敏感和去势抵抗性前列腺癌中相似。
要点
- 定量PPP列线图在内部和外部验证队列的C指数分别为0.80和0.77。
- 定量PPP列线图在初始分期中优于STARCAP(AUC 0.73 vs 0.54,p=0.018)。
- 定量PPP列线图在生化复发中优于EAU(AUC 0.69 vs 0.52,p<0.0001)。
核心结论
- PPP列线图能准确分层早期和晚期前列腺癌的总生存高风险与低风险组,预测准确性等于或优于现有临床风险工具。
- 列线图的验证与改进正在长期随访中进行(NCT06320223)。
研究设计与样本
- 多中心回顾性研究,纳入2014年10月30日至2021年12月27日在德国埃森、明斯特、弗赖堡和德累斯顿大学医院接受PSMA-PET的组织学确诊前列腺癌患者。
- 埃森大学医院患者按2:1随机分配至开发队列或内部验证队列,明斯特、弗赖堡和德累斯顿大学医院患者纳入外部验证队列。
- 共分析2414例男性患者,其中开发队列1110例、内部验证队列502例、外部验证队列802例。
- 截至数据截止日2023年6月30日,901例(37%)死亡,中位随访52.9个月(IQR 33.9-79.0)。
- 使用开发队列基于Cox回归模型构建定量和可视化PPP列线图,以总生存为主要终点,采用LASSO惩罚。
主要发现
- 定量PPP列线图的预测因子为区域淋巴结转移(分子影像N2)、远处转移(盆腔外淋巴结转移、骨转移[弥漫或弥漫性骨髓受累]和器官转移)、肿瘤体积(L)和肿瘤平均标准化摄取值。
- 可视化PPP列线图的预测因子为远处转移(盆腔外淋巴结转移、骨转移[弥漫或弥漫性骨髓受累]和器官转移)和总肿瘤病灶数。
- 定量列线图在内部和外部验证队列的C指数分别为0.80(95%CI 0.77-0.84)和0.77(0.75-0.78)。
- 可视化列线图在内部和外部验证队列的C指数分别为0.78(0.75-0.82)和0.77(0.75-0.78)。
- 在开发与内部验证合并队列中,定量PPP列线图预测总生存优于STARCAP初始分期(n=139,AUC 0.73 vs 0.54,p=0.018)、EAU生化复发(n=412,0.69 vs 0.52,p<0.0001)和NCCN全分期(n=1534,0.81 vs 0.74,p<0.0001),但与GAFITA在mHSPC(n=122,0.76 vs 0.72,p=0.49)和mCRPC(n=270,0.67 vs 0.75,p=0.20)中相似。
关键数值与推荐
- 定量PPP列线图内部验证C指数0.80(95%CI 0.77-0.84),外部验证0.77(0.75-0.78)。
- 可视化PPP列线图内部验证C指数0.78(0.75-0.82),外部验证0.77(0.75-0.78)。
- 定量PPP列线图 vs STARCAP初始分期:AUC 0.73 vs 0.54(n=139,p=0.018)。
- 定量PPP列线图 vs EAU生化复发:AUC 0.69 vs 0.52(n=412,p<0.0001)。
- 定量PPP列线图 vs NCCN全分期:AUC 0.81 vs 0.74(n=1534,p<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate-specific membrane antigen (PSMA)-PET was introduced into clinical practice in 2012 and has since transformed the staging of prostate cancer. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria were proposed to standardise PSMA-PET reporting. We aimed to compare the prognostic value of PSMA-PET by PROMISE (PPP) stage with established clinical nomograms in a large prostate cancer dataset with follow-up data for overall survival. METHODS: In this multicentre retrospective study, we used data from patients of any age with histologically proven prostate cancer who underwent PSMA-PET at the University Hospitals in Essen, Münster, Freiburg, and Dresden, Germany, between Oct 30, 2014, and Dec 27, 2021. We linked a subset of patient hospital records with patient data, including mortality data, from the Cancer Registry North-Rhine Westphalia, Germany. Patients from Essen University Hospital were randomly assigned to the development or internal validation cohorts (2:1). Patients from Münster, Freiburg, and Dresden University Hospitals were included in an external validation cohort. Using the development cohort, we created quantitative and visual PPP nomograms based on Cox regression models, assessing potential PPP predictors for overall survival, with least absolute shrinkage and selection operator penalty for overall survival as the primary endpoint. Performance was measured using Harrell's C-index in the internal and external validation cohorts and compared with established clinical risk scores (International Staging Collaboration for Cancer of the Prostate [STARCAP], European Association of Urology [EAU], and National Comprehensive Cancer Network [NCCN] risk scores) and a previous nomogram defined by Gafita et al (hereafter referred to as GAFITA) using receiver operating characteristic (ROC) curves and area under the ROC curve (AUC) estimates. FINDINGS: We analysed 2414 male patients (1110 included in the development cohort, 502 in the internal cohort, and 802 in the external validation cohort), among whom 901 (37%) had died as of data cutoff (June 30, 2023; median follow-up of 52·9 months [IQR 33·9-79·0]). Predictors in the quantitative PPP nomogram were locoregional lymph node metastases (molecular imaging N2), distant metastases (extrapelvic nodal metastases, bone metastases [disseminated or diffuse marrow involvement], and organ metastases), tumour volume (in L), and tumour mean standardised uptake value. Predictors in the visual PPP nomogram were distant metastases (extrapelvic nodal metastases, bone metastases [disseminated or diffuse marrow involvement], and organ metastases) and total tumour lesion count. In the internal and external validation cohorts, C-indices were 0·80 (95% CI 0·77-0·84) and 0·77 (0·75-0·78) for the quantitative nomogram, respectively, and 0·78 (0·75-0·82) and 0·77 (0·75-0·78) for the visual nomogram, respectively. In the combined development and internal validation cohort, the quantitative PPP nomogram was superior to STARCAP risk score for patients at initial staging (n=139 with available staging data; AUC 0·73 vs 0·54; p=0·018), EAU risk score at biochemical recurrence (n=412; 0·69 vs 0·52; p<0·0001), and NCCN pan-stage risk score (n=1534; 0·81 vs 0·74; p<0·0001) for the prediction of overall survival, but was similar to GAFITA nomogram for metastatic hormone-sensitive prostate cancer (mHSPC; n=122; 0·76 vs 0·72; p=0·49) and metastatic castration-resistant prostate cancer (mCRPC; n=270; 0·67 vs 0·75; p=0·20). The visual PPP nomogram was superior to EAU at biochemical recurrence (n=414; 0·64 vs 0·52; p=0·0004) and NCCN across all stages (n=1544; 0·79 vs 0·73; p<0·0001), but similar to STARCAP for initial staging (n=140; 0·56 vs 0·53; p=0·74) and GAFITA for mHSPC (n=122; 0·74 vs 0·72; p=0·66) and mCRPC (n=270; 0·71 vs 0·75; p=0·23). INTERPRETATION: Our PPP nomograms accurately stratify high-risk and low-risk groups for overall survival in early and late stages of prostate cancer and yield equal or superior prediction accuracy compared with established clinical risk tools. Validation and improvement of the nomograms with long-term follow-up is ongoing (NCT06320223). FUNDING: Cancer Registry North-Rhine Westphalia.
引用
- Karpinski MJ, Hüsing J, Claassen K, et al. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. Lancet Oncol. 2024. PMID: 39089299. doi:10.1016/S1470-2045(24)00326-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。